Santhera Announces Publication on Molecular Distinctions of Vamorolone Compared to Corticosteroids

Pratteln, Switzerland, and Rockville, MD, USA, September 14, 2020

Santhera Pharmaceuticals (SIX: SANN) announces that Emory University scientists and partner ReveraGen Biopharma Inc. have published new data on the molecular mode of action of vamorolone compared to standard corticosteroids